Arcadia Biosciences, Inc.
RKDA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -10.5% | 21.3% | -1.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 32.1% | 43.4% | 43.2% | 32% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | $0 |
| Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -88.5% | -34.4% | 44.2% | -187.4% |
| Other Income/Exp. Net | $0 | -$0 | $0 | -$0 |
| Pre-Tax Income | $0 | -$0 | $0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | -$0 | $0 | -$0 |
| % Margin | 65.7% | -306.4% | 216.6% | -334.2% |
| EPS | 0.62 | -3.26 | 1.9 | -1.18 |
| % Growth | 119% | -271.6% | 261% | – |
| EPS Diluted | 0.62 | -3.26 | 1.9 | -1.18 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 65.9% | -102.1% | -100.6% | -185.7% |